Overview

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$4.20
Change (%) Stock is Down 0.02 (0.47%)
Volume72,713
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
04/05/18TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
Keynote Speaker, Dr. Rudolph E. Tanzi, will sign copies of his new book, “The Healing Self,” at the TRU NIAGEN booth IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its cutting-edge form of vitamin B3, TRU NIAGEN, at the American Academy of Anti-Aging Medicine Spring Congress, Booth #1020, taking place April 12-14 in Hollywood, FL.... 
Printer Friendly Version
03/29/18New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
Findings from the University of Colorado, Boulder Study Suggest Future Studies Should Focus on the Therapeutic Potential for Blood Pressure and Vascular Health IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a cutting-edge form of vitamin B3, led by Christopher Martens, PhD and Douglas Seals, PhD, of... 
Printer Friendly Version
03/08/18ChromaDex Corporation Reports 2017 Financial Results   
Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full year 2017 financial results. Results of operations for the three months ended Dec. 30, 2017 For the three months ended Dec. 30, 2017 (“Q4 2017”), ChromaDex reported net sales from continuing operations of $7.... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2017 Annual Report on Form 10K
Download DocumentationSpecial Meeting – Proxy Statement
Download Documentation2017 Proxy Statement
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.